Conversion Surgery for Pancreatic Cancer—The Impact of Neoadjuvant Treatment
Pancreatic ductal adenocarcinoma (PDAC) has still a dismal prognosis, mainly because only 15–20% of all patients present with resectable tumor stages at the time of diagnosis. Due to locally extended tumor growth or distant metastases upfront resection is not reasonable in the majority of patients....
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2020-01-01
|
| Sarja: | Frontiers in Oncology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/article/10.3389/fonc.2019.01501/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|